VANCOUVER, Wash., Dec. 22, 2017 /PRNewswire/ — AbSci announced today the appointment of Fred Larimore, PhD to AbSci’s Scientific Advisory Board. Dr. Larimore brings over 30 years of experience in biopharmaceutical manufacturing and process development at leading pharmaceutical companies, includes in management roles at companies such as Cook Pharmica and Eli Lilly. Prior to formally joining AbSci’s Scientific Advisory Board, Dr. Larimore advised AbSci on various aspects of biopharmaceutical process development manufacturing scale-up.
“It is an exciting opportunity to join AbSci’s Scientific Advisory Board,” said Dr. Larimore. “People in the industry have been talking about folding protein in E. coli for years. Before it was just theoretically possible, but the SoluPro Platform now makes it technically possible to fold full-length antibodies and proteins within E. coli.”
Dr. Larimore worked for over 25 years at Eli Lilly, where he served as a Research Fellow and senior scientific leader. He has extensive experience in process design, development, scale-up, and manufacturing, and led manufacturing support of six major biotechnology products in the marketplace, Xigris®, Humulin®, Humalog®, Humatrope®, Forteo® and Recombinant Human Glucagon. He was influential in developing some of the original biologic manufacturing processes, including production of Human Insulin using the chain route (Humulin®), Human Insulin using the proinsulin process (Humulin®), Human Growth Hormone (Humatrope®), Recombinant Human Parathyroid Hormone (Forteo®), Factor IX and several other monoclonal antibodies.
Dr. Larimore is a founding member and Vice President of the Board of Directors of the Society for Bioprocessing Professionals (SBP) and currently serves as the Principal Consultant at Sierra Vista Biotech Consulting. He was also the Vice President of Scientific Affairs and Chief Scientific Officer of Cook Parmica. Dr. Larimore holds a B.A. in Chemistry from St. Olaf College, a Ph.D. in Biochemistry from the University of Minnesota, and completed his post-doctoral training at the Harvard Medical School, Department of Physiology.
AbSci is a global leader in biomanufacturing technologies. The company’s SoluPro™ expression platform achieves ultra-high yields of soluble and active protein products and enables ultra-high efficiency purification processes. AbSci’s unique approach accelerates drug discovery timelines, increases manufacturing efficiencies, and drastically reduces costs for the biopharmaceutical industry. For more information, please visit www.abscibio.com.